Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort by Morelle, Guillaume et al.
HAL Id: hal-02316496
https://hal-normandie-univ.archives-ouvertes.fr/hal-02316496
Submitted on 16 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Chronic and recurrent non-infectious paediatric-onset
uveitis: a French cohort
Guillaume Morelle, Julie Gueudry, Florence Uettwiller, Carine Wouters,
Brigitte Bader-Meunier, Mathieu Robert, Dominique Monnet, Bahram
Bodaghi, Martine Grall-Lerosey, Pierre Quartier
To cite this version:
Guillaume Morelle, Julie Gueudry, Florence Uettwiller, Carine Wouters, Brigitte Bader-Meunier, et
al.. Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort. RMD Open :
Rheumatic & Musculoskeletal Diseases, EULAR ; BMJ, 2019, 5 (2), pp.e000933. ￿10.1136/rmdopen-
2019-000933￿. ￿hal-02316496￿
  1Morelle G, et al. RMD Open 2019;5:e000933. doi:10.1136/rmdopen-2019-000933
Original article
Chronic and recurrent non-infectious 
paediatric-onset uveitis: a French cohort
Guillaume Morelle,   1,2 Julie Gueudry,3 Florence Uettwiller,4 Carine Wouters,1,2,4 
Brigitte Bader-Meunier,1,2 Mathieu P Robert,2,5,6 Dominique Monnet,2,7 
Bahram Bodaghi,8 Martine Grall-lerosey,9 Pierre Quartier   1,2
To cite: Morelle g, gueudry J, 
Uettwiller F, et al. chronic 
and recurrent non-infectious 
paediatric-onset uveitis: a 
French cohort. RMD Open 
2019;5:e000933. doi:10.1136/
rmdopen-2019-000933
received 25 February 2019
revised 17 June 2019
accepted 23 June 2019
For numbered affiliations see 
end of article.
Correspondence to
Pr Pierre Quartier;  
 pierre. quartier@ aphp. fr
Paediatric rheumatology
© author(s) (or their 
employer(s)) 2019. re-use 
permitted under cc BY-nc. no 
commercial re-use. See rights 
and permissions. Published 
by BMJ.
AbstrAct
Objective to evaluate the demographics, aetiologies, 
complications, treatments and visual prognoses of chronic 
and recurrent non-infectious paediatric-onset uveitis in 
France.
Methods Descriptive, retrospective and bicentric study in 
patients whose disease started before 17 and who were 
followed up in two centres from January 2010 to May 2017.
Results We included 147 patients with 268 affected eyes. 
eighty-two had juvenile idiopathic arthritis-associated 
chronic uveitis, 58 were antinuclear antibody (ana) positive 
and 24 were ana negative, 36 had idiopathic uveitis, 9 
had enthesitis-related arthritis-associated uveitis, 9 had 
sarcoidosis-associated uveitis and 11 had other inflammatory 
aetiologies. these patients cumulated 161 complications: 
ocular hypertension, cataract, band keratopathy, macular 
oedema, optic disk oedema and decreased visual acuity, 
including permanent visual loss for 31 patients. the most 
used treatments were corticosteroid (cS) eye drops (82%), 
systemic cSs (34%), methotrexate (58%) and biologics 
(38%). at the latest follow-up, 45 patients had achieved 
remission of uveitis without any treatment, 56 had inactive 
uveitis on topical steroids and 48 still had active uveitis.
Conclusion Paediatric-onset uveitis are associated 
with a high rate of complications. However, following the 
introduction of biologics and particularly antitumour necrosis 
factor alpha antibodies, a significant proportion of uveitis 
became inactive on or even off treatment.
InTROduCTIOn
Paediatric uveitis is a rare but severe disease, 
leading to ocular complications in 30%–60% 
of patients1 2 and legal blindness in 7%–23% 
of patients.3 4 Paediatric uveitis must be distin-
guished from adult uveitis with regard to its 
manifestations, aetiology and management. 
The overall incidence and prevalence of paedi-
atric uveitis are estimated to be 4.9 and 30.0 per 
100 000 children in Europe and America5–8
In most cases, pediatric-onset non-infectious 
chronic uveitis (pNICU) is associated with 
early-onset, antinuclear antibody (ANA)-pos-
itive juvenile idiopathic arthritis (JIA). Both 
the aetiological diagnosis and treatment of 
pNICU are a challenge. Corticosteroids (CSs) 
and immunomodulatory drugs are the most 
common treatments.5 9–11 Topical CSs are indi-
cated for non-infectious, anterior paediatric 
uveitis as first line, regardless of the aetiology. 
However, long-term CS therapy is associated 
with side effects, including ocular hyper-
tension (OHT) and cataract. Methotrexate 
(MTX) has been widely used as second-line 
therapy.12 Biologics and in particular antitu-
mour necrosis factor (TNF) alpha treatments 
demonstrated, their efficacy, particularly in 
JIA-associated or idiopathic anterior pNICU in 
children13–16 and intermediate, posterior and 
panuveitis in adults.17 However, there are still 
few data on patients’ medium-term to long-
term outcomes at the era of biological therapy. 
Here, we analysed the aetiologies, characteris-
tics and outcome of pNICU or pediatric-onset 
recurrent uveitis in patients followed up in two 
French tertiary care centres.
MaTeRIals and MeThOds
This was a retrospective, observational, 
descriptive study of patients with pNICU or 
paediatric-onset non-infectious recurrent 
uveitis followed between 2010 and 2017 in 
two French tertiary care centres: Necker 
Key messages
What is already known about this subject?
 ► Uveitis is known to be a severe complication of in-
flammatory diseases.
What does this study add?
 ► this retrospective study establishes an overview 
of medical practices with a large cohort of patients 
with non-infectious paediatric-onset chronic or re-
current uveitis.
how might this impact on clinical practice?
 ► Joint care between paediatric rheumatologists and 
ophthalmologists is essential to prevent uveitis-re-
lated complications.
 ► Biotherapies show promising results with a good ef-
ficacy and tolerance in uveitis management.
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Figure 1 Flowchart. JIA, juvenile idiopathic arthritis.
Enfants-Malades Hospital in Paris and the University 
Hospital of Rouen. The exclusion criteria were infectious 
uveitis, age over 16 at uveitis onset or incomplete data. 
Medical reports were examined by a paediatrician experi-
enced in paediatric rheumatology and an opthalmologist 
(figure 1).
Patients’ files were collected using the French database 
for rare diseases, CEMARA,18 with an agreement of the 
French Commission Nationale Informatique et Libertés.
Data retrieval and analysis included ocular and systemic 
symptoms, personal and family medical history, current 
age, age at diagnosis of uveitis, age at first visit, gender, 
laterality of the uveitis, duration and course of the disease, 
and follow-up period. We recorded any inflammatory 
syndrome (elevated erythrocyte sedimentation rate or 
C reactive protein) only at the uveitis diagnosis. We also 
recorded auto-antibody (including ANA), elevated ACE, 
positivity of HLA B27, visual acuity (VA) at presentation 
and at the last visit, use of local and/or systemic medical 
therapies, ocular surgeries and complications occurring 
at any time point.
We collected six different types of aetiologies: ANA+JIA, 
ANA−JIA, enthesitis-related arthritis (defined by the 
occurrence of arthritis and enthesitis and at least two of 
the following criteria: sacroiliac pain and/or inflamma-
tory rachialgia, acute anterior uveitis, presence of HLA 
B27), sarcoidosis, idiopathic uveitis and other inflamma-
tory diseases.
The recorded complications included band keratop-
athy, posterior synechiae, OHT, which was defined by an 
intraocular pressure greater than 21 mm Hg, glaucoma 
(hypertension associated with lesions of the optic nerve), 
cataract, macular oedema (detected by optical coherence 
tomography), papilloedema, posterior synechiae, band 
keratopathy and decrease VA. All data were collected at 
diagnosis of uveitis; at 6, 12 and 24 months; and at the 
latest follow-up.
The diagnosis of uveitis was established based on the 
recommendations of the International Standardisation 
of Uveitis Nomenclature. The uveitis was classified as 
anterior, intermediate, posterior or panuveitis, based on 
its level of inflammation, which was established by the 
grading of the cells and flare in the anterior chamber 
and haze in the vitreous. The course and duration of 
uveitis were also based on the SUN guidelines.19 20
The SUN criteria were applied to determine if the 
uveitis was recurrent (repeated episodes separated by 
periods of inactivity without treatment >3 months after 
discontinuing treatment) or chronic (chronic persistent 
uveitis with a relapse within 3 months after discontinuing 
treatment). The severity of inflammation was graded on 
a scale of 0–4. Improvement was defined by a decrease 
of at least 2 points and aggravation by an increase of at 
least 2 points or worsening from 3 to 4 according to the 
SUN. Patients with inactive disease for at least 6 months 
after discontinuation of all treatments for eye disease 
(including CS eye drops) were considered in remission. 
The active uveitis was characterised according to Stan-
dardization of Uveitis Nomenclature (SUN) criteria 
(grade cells >1) as for inactive uveitis (grade 0 cells 
applies to the anterior chamber).
ResulTs
Patient characteristics
Patient characteristics are summarised in table 1.
One hundred forty-seven paediatric patients with uveitis 
were identified and 107 (74 %) were female. Uveitis was 
discovered during a systematic consultation in 50 patients 
(either during the initial consultation or during ophthal-
mological follow-up) and before the manifestation of any 
arthritic or systemic symptom in nine patients. The most 
common diagnoses were JIA-associated uveitis (82/147, 
56%) and idiopathic uveitis (36/147, 25%). Other base-
line characteristics are summarised in table 1.
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Treatments
One hundred twenty-one patients were treated in first 
intention with topical CS alone or in combination. Oral 
CSs were used in 51 out of 147 patients (34%) and intra-
venous CSs were used in 12 (8%). Twenty-eight patients 
with JIA had CS (34% of JIA-related uveitis) and 23 were 
not JIA related (36%)
Disease-modifying antirheumatic drugs (DMARDs) 
were used as second-line therapy in 88 patients (62%), 
MTX was used in 84 patients and azathioprine in 4.
Sixty patients (41%) underwent biological treatment 
alone or in combination with MTX: adalimumab in 44 
patients (73 %), etanercept in 7, 4 of whom failed to 
respond and had to switch to adalimumab, tocilizumab 
in 1 patient, and anakinra and abatacept in 2 patients 
each.
If we analyse the differences in management before 
and after 2010, we have two groups of uveitis: before 2010 
(n=42) and after 2010 (n=105).
The delay between the diagnosis and the introduction 
of DMARDs is 20.8 months (n–N: 0–84) before 2010 and 
8.7 months (n–N: 0–36) after 2010.
The delay between the DMARDs and the biologic 
agents is 25 months (n–N: 0–84) before 2010 and 11.5 
months (n–N: 0–29) after 2010.
At the last consultation, 46 patients had active uveitis, 
56 had inactive uveitis still undergoing treatment and 
45 had uveitis in complete remission off treatment. We 
identified three situations at the last follow-up: uveitis 
in remissions according to SUN criteria in patients with 
an inactive disease for at least 6 months after discontin-
uing topical CS, active uveitis according to SUN (grade 
cells >0) and inactive uveitis (grade 0 cells in the anterior 
chamber according to the SUN) under treatment.
Patients with active uveitis or inactive uveitis on topical Cs
Among 104 patients still receiving topical CS at the latest 
follow-up, 56 had inactive uveitis; the distribution by 
aetiology is described in table 2. Additionally, out of 16 
patients under oral CS treatment during the follow-up, 8 
still had oral CS it at the last visit. Thirty-six patients had 
received MTX, as a sole immunomodulatory drug in 7 
patients or in 29 patients who had failed to respond to 
MTX monotherapy, combined to a biologic agent. The 
biologics used were adalimumab for 23 patients (20 JIA, 
2 idiopathic uveitis and 1 Behçet disease) and etanercept 
for 2 patients, 1 of whom had to switch to adalimumab 
for non-response.
Among 104 patients still on topical CS at the latest 
follow-up, 48 still had active uveitis, 26 were classified 
as SUN 0.5 and 21 were classified as SUN 1. No case of 
uveitis with an inflammation level higher than SUN 1+ 
was observed.
In addition to topical CS, among 16 patients under oral 
steroids during the follow-up, 9 were still on oral steroids 
at the last visit. Thirty patients had MTX, 7 patients had 
MTX as monotherapy and 23 patients had MTX associ-
ated with biologics (14 ANA+JIA and ANA−JIA, 4 JIA, 
3 idiopathic uveitis and 2 sarcoidosis). The biologic 
used for 24 patients was adalimumab. Two patients had 
received etanercept but had switched to adalimumab 
after 1 year, and one patient was on tocilizumab. In most 
cases, the use of biological treatment was associated with 
improvement of uveitis. Regarding side effects under 
biological treatment, one patient had an anaphylactic 
reaction to adalimumab and was switched to abatacept, 
and one patient had psychiatric disorders on adalim-
umab. There were three infections requiring hospitalisa-
tion, no opportunistic infection and no death.
Patients with inactive uveitis off steroids at the latest follow-
up
Patients with uveitis in remissions are described in 
table 2. All patients had first been treated with topical CS, 
and 23 patients had CS as monotherapy. Eighteen had 
been treated with MTX, 2 of whom stopped for hepatic 
cytolysis. Eleven patients were still on MTX at the last 
visit, and MTX was associated with biologics in four cases. 
They had all stopped steroid treatment (topical and 
systemic steroids). Thirteen patients received biologics 
(adalimumab in 8, etanercept in 3, abatacept in 1 and 
anakinra), 3 patients were able to stop adalimumab and 
1 patient received etanercept.
Complications
Complications are summarised in tables 3 and 4.
The most frequent complication was OHT, which 
affected 53 patients (36 %) and 111 eyes. In 16 patients, 
it was already present at the time of diagnosis, in 34 cases 
it was observed at 12 months, and later in 13 other cases. 
Thirty-one patients developed cataract, which was present 
at diagnosis in 8, at 12 months in 9 and at 24 months 
in 14. Band keratopathy was observed in 19 patients; at 
diagnosis in 10, at 12 months in 3 and at 24 months in 6. 
Seventeen patients had a macular oedema, 14 patients 
were diagnosed during the first ophthalmological consul-
tation and 5 were diagnosed at 12 months. Thirty-seven 
patients had optic disc oedema, 31 at diagnostic and 6 at 
12 months.
VA impairment is shown in table 4. No patient fulfilled 
the criteria of bilateral legal blindness (ie, best corrected 
VA <0.1 decimal Snellen in the better eye). Unilateral 
blindness was documented in 17/147 (11%). Six patients 
had unilateral VA impairment (VA <0.3 decimal Snellen), 
and eight patients had bilateral VA impairment. The 
most frequent cause of blindness was macular oedema, 
and the most frequent causes of visual impairment were 
macular oedema and cataract.
dIsCussIOn
In this retrospective study, we report a large cohort of 
patients with non-infectious paediatric-onset chronic or 
recurrent uveitis. We observed that uveitis was bilateral, 
anterior, idiopathic or associated to ANA+JIA in most 
cases. The study shows that a high proportion of patients 
Enseignem
ent Superieur (ABES). Protected by copyright.
 o
n
 O
ctober 16, 2019 at Agence Bibliographique de l
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-000933 on 5 August 2019. Downloaded from
 
7Morelle g, et al. RMD Open 2019;5:e000933. doi:10.1136/rmdopen-2019-000933
Paediatric rheumatology
Table 3 Cumulative complications
Cohort
(n=147)
JIA+ANA 
(n=58)
JIA−ANA
(n=24_
ERA
(n=9)
Idiopathic uveitis 
(n=36)
Sarcoidosis
(n=9)
Other uveitis
(n=11)
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Patient with a complication 101 (69) 43 (72) 17 (70) 2 (22) 24 (67) 9 6 (54)
OHT 57 (39) 29 (50) 10 (42) 2 (22) 8 (22) 4 (44) 4 (36)
OHT surgery 13 (23) 7 (24) 4 (40) – 2 (25) – –
Cataract 32 (22) 17 (29) 10 (42) – 2 (5) 1 (11) 2 (18)
Cataract surgery 13 (38) 4 (23) 4 (40) – 2 (100) 1 (100) 2 (100)
Band keratopathy 19 (13) 10 (17) 4 (17) – 5 (13) – –
Macular oedema 19 (13) 7 (12) 3 (12) – 4 (11) 3 (33) 2 (18)
Optic disk oedema 37 (26) 11 (19) 5 (21) – 6 (17) 9 6 (54)
ANA, antinuclear antibody; ERA, enthesitis-related arthritis; JIA, juvenile idiopathic arthritis; OHT, ocular hypertension.
achieve inactive uveitis, with or without complications, 
essentially after treatment with MTX or biologics.
This higher rate of JIA in our study compared with 
other reports5 6 21–23 may be related to a selection bias; 
indeed, patients had been referred to two paediatric 
rheumatology centres.
We observed a high level of complication; this rate is 
comparable for patients with JIA-associated uveitis with 
that found by Marvillet et al24; Paroli et al1 found a compa-
rable rate of complications as well. Sardar et al25 also 
found a similar rate also in non-JIA uveitis. Regarding 
patients’ visual outcome, results from different reports 
were not always consistent together: Kump et al reported 
a VA <20/40 in 23% of children with uveitis, de Boer et 
al reported a VA <20/200 in 19% of cases. Thorne et al 
reported a VA <20/200 in 23%.2 4 26
In this study, at the end of the follow-up period, only 
8% of the eyes had a VA <20/200 and no patients only 
had a VA <20/200. In our study, visual outcomes in chil-
dren with AIJ-related uveitis are good in our study, as 
shown in other recent series.4 26–28
Among the complications, OHT was documented 
more frequently than in other publications.1 5 27 29 30 Most 
cases of OHT occurred in patients with JIA-associated or 
sarcoidosis-associated uveitis. Also, the rate of this compli-
cation increases in patients with a longer period between 
uveitis onset and the referral to the tertiary care centre, 
especially after several years of active uveitis, as described 
in other series.30 31
Chronic inflammation and long-lasting local steroid 
treatment are the two causes widely reported in the OHT 
literature. We know that one of the particularities in chil-
dren is the high frequency of cortisone OHTs. In chil-
dren, it is difficult to distinguish whether symptoms are 
treatment related or a result of chronic inflammation. 
Similarly, cataracts were mostly diagnosed in patients 
with long-lasting active uveitis, who were also undergoing 
prolonged local steroid treatment.
We noticed a high prevalence of papilloedema, 
synechiae and CMO at diagnosis. We found that there 
are two peaks of incidence of complications: the 
diagnosis of uveitis and 12–18 months of evolution of 
uveitis under treatment. This result is interesting as this 
finding supports the importance of early diagnosis and 
management of effective and steroid-sparing treatments 
in pNICU, whatever the aetiology.
We found more complications in the ANA+JIA group 
than in any other groups, which is in line with the diffi-
culty of early diagnosis in such patients.26 32–34
The frequency of use of CSs (orally or intravenously) 
is quite high in this current series. For uveitis not associ-
ated with JIA, this result is not surprising and is consistent 
with other studies.25 35 For the AJI group, this result is 
high, but the patients involved are in the majority of cases 
either severe forms (articular and ocular) or patients 
whose follow-up began in the early 2000s, where there 
were little therapeutic alternatives.
The high proportion of patients who received non-bio-
logical or biological DMARDs may be linked to a selection 
bias, as these patients had been referred to tertiary care 
paediatric rheumatology centres. However, the increase 
in the use of DMARDs, particularly biological DMARDs, 
after 2010 indicates a tendency to use such treatments 
more frequently in this context, as also reported in other 
countries.5 36 37 The more frequent and earlier introduc-
tion of DMARDs in patients treated after 2010 was likely 
linked to a better communication between ophthalmolo-
gists and paediatricians. Indeed, in recent years, thanks to 
the work of associations, a national effort for rare diseases 
has been conducted in France. This allowed the develop-
ment of more common efforts, such as collaborative trials14 
and common web conferences. So even in the absence 
of joint outpatient clinics, the communication between 
ophthalmologists and paediatricians has improved. It was 
associated in our series with a lower rate of complications 
at the latest follow-up, although the follow-up duration 
was shorter than that in patients treated before 2010. As 
recent controlled trials demonstrated the efficacy of the 
anti-TNF antibody adalimumab in controlling pediat-
ric-onset idiopathic or JIA-associated uveitis14 15 and other 
efforts are on-going with other biologics, more and more 
patients should receive such treatments in the long run.
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Among the biological therapies, we have a majority of 
adalimumab, with good efficiency. The second biolog-
ical therapy is etanercept. This treatment, which was well 
tolerated in the majority of cases, was less used than adali-
mumab. In the literature, etanercept has been suspected 
of causing uveitis,38 but it is not clear whether uveitis, 
during etanercept monotherapy, is a paradoxical effect 
or an inadequate response to biological therapy.39 In our 
cohort, we did not see evidence that etanercept precipi-
tated a flare in uveitis, but rather a lack of efficacy that led 
to a change in biological therapy.
Looking into the occurrence of long-term compli-
cations while under biotherapy, we have not seen a 
difference between biological biotherapies (infliximab, 
etanercept or adalimumab), but this should be nuanced 
by the different sizes of the groups.
Only a few patients had infliximab in our series. This 
is probably due to the fact that 60% of our patients had 
uveitis related to JIA, and in this type of uveitis, although 
infliximab is an option, adalimumab is more often used. 
Indeed, even before it was authorised for JIA-associated 
uveitis, adalimumab had been approved for the treat-
ment of JIA with polyarticular involvement and an inade-
quate response to MTX.
In conclusion, we report a large descriptive, retro-
spective cohort of non-infectious paediatric uveitis. The 
complication rate in our cohort was high, but tended to 
be lower in more recently diagnosed patients who likely 
benefited from earlier introduction of highly effective 
treatments such as monoclonal anti-TNF alpha anti-
bodies. In recently diagnosed patients, a longer follow-up 
is needed to confirm the long-term efficacy and safety of 
these treatments.
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